BioCentury | Dec 13, 2019
Clinical News

Phase II miss dims outlook for Biogen’s anti-tau mAb from Bristol deal

...agreement included another $960 million in milestones plus royalties, including potential payments to shareholders of iPierian Inc....
BioCentury | Oct 28, 2017
Strategy

Biogen doubles down

...payments, plus royalties, from Biogen. Biogen also assumes the remaining obligations to former shareholders of iPierian Inc....
BioCentury | Apr 14, 2017
Company News

BMS, Biogen deal

...for up to $550 million in milestones plus royalties owed by BMS to shareholders of iPierian Inc....
...would include a $60 million milestone upon the molecule's advancement beyond Phase I. BMS acquired iPierian...
BioCentury | Apr 13, 2017
Company News

BMS out-licenses programs to Biogen, Roche

...for up to $550 million in milestones plus royalties owed by BMS to shareholders of iPierian...
...would include a $60 million milestone upon the molecule's advancement beyond Phase I. BMS acquired iPierian...
BioCentury | Oct 5, 2015
Finance

Asceneuron's clinical path

...you need to take the company to registration." Last year, Bristol-Myers Squibb Co. (NYSE:BMY) acquired iPierian Inc....
BioCentury | Apr 13, 2015
Finance

OrbiMed turns True North

...Vlasselaer have a "history of success." The pair held the same roles at neurology play iPierian Inc....
...NYSE:BMY) acquired last year for up to $725 million. True North was spun out of iPierian...
BioCentury | Apr 8, 2015
Top Story

OrbiMed leads $35M round for True North

...The biotech, which closed a $22 million A round in June 2014, spun out from iPierian Inc....
BioCentury | Jun 23, 2014
Financial News

True North Therapeutics completes venture financing

...comes from iPierian Inc. , which spun out True North last year to develop TNT009 . iPierian...
...round also participated in iPierian’s venture round. Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.) acquired iPierian...
BioCentury | Jun 18, 2014
Financial News

True North closes $22 million A round

...round comes from iPierian Inc. , which spun out True North last year to develop TNT009. iPierian...
...North's series A round also participated in iPierian's venture round. Bristol-Myers Squibb Co. (NYSE:BMY) acquired iPierian...
BioCentury | May 12, 2014
Analyst Picks & Changes

Analyst picks & changes

...Health Sciences to develop iPSC products. Leonard also said the April acquisition of iPSC play iPierian Inc....
Items per page:
1 - 10 of 49
BioCentury | Dec 13, 2019
Clinical News

Phase II miss dims outlook for Biogen’s anti-tau mAb from Bristol deal

...agreement included another $960 million in milestones plus royalties, including potential payments to shareholders of iPierian Inc....
BioCentury | Oct 28, 2017
Strategy

Biogen doubles down

...payments, plus royalties, from Biogen. Biogen also assumes the remaining obligations to former shareholders of iPierian Inc....
BioCentury | Apr 14, 2017
Company News

BMS, Biogen deal

...for up to $550 million in milestones plus royalties owed by BMS to shareholders of iPierian Inc....
...would include a $60 million milestone upon the molecule's advancement beyond Phase I. BMS acquired iPierian...
BioCentury | Apr 13, 2017
Company News

BMS out-licenses programs to Biogen, Roche

...for up to $550 million in milestones plus royalties owed by BMS to shareholders of iPierian...
...would include a $60 million milestone upon the molecule's advancement beyond Phase I. BMS acquired iPierian...
BioCentury | Oct 5, 2015
Finance

Asceneuron's clinical path

...you need to take the company to registration." Last year, Bristol-Myers Squibb Co. (NYSE:BMY) acquired iPierian Inc....
BioCentury | Apr 13, 2015
Finance

OrbiMed turns True North

...Vlasselaer have a "history of success." The pair held the same roles at neurology play iPierian Inc....
...NYSE:BMY) acquired last year for up to $725 million. True North was spun out of iPierian...
BioCentury | Apr 8, 2015
Top Story

OrbiMed leads $35M round for True North

...The biotech, which closed a $22 million A round in June 2014, spun out from iPierian Inc....
BioCentury | Jun 23, 2014
Financial News

True North Therapeutics completes venture financing

...comes from iPierian Inc. , which spun out True North last year to develop TNT009 . iPierian...
...round also participated in iPierian’s venture round. Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.) acquired iPierian...
BioCentury | Jun 18, 2014
Financial News

True North closes $22 million A round

...round comes from iPierian Inc. , which spun out True North last year to develop TNT009. iPierian...
...North's series A round also participated in iPierian's venture round. Bristol-Myers Squibb Co. (NYSE:BMY) acquired iPierian...
BioCentury | May 12, 2014
Analyst Picks & Changes

Analyst picks & changes

...Health Sciences to develop iPSC products. Leonard also said the April acquisition of iPSC play iPierian Inc....
Items per page:
1 - 10 of 49